With the present work, we report ZAR1 as a cancer biomarker and also elucidate its role in human cancer using state-of-the-art methylation sequencing, transcriptomic approaches, mass spectrometry for the identification of interacting partners, and epigenetic reactivation by CRISPR-dCas9. This evidence concerns the gene ZAR1 and cancer.